Amedeo Smart

Free Medical Literature Service

 

Amedeo

Alzheimer's Disease
  Free Subscription

Articles published in
Ann Neurol
    April 2024
  1. GARCIA-CORDERO I, Anastassiadis C, Khoja A, Morales-Rivero A, et al
    Evaluating the Effect of Alzheimer's Disease-Related Biomarker Change in Corticobasal Syndrome and Progressive Supranuclear Palsy.
    Ann Neurol. 2024 Apr 5. doi: 10.1002/ana.26930.
    >> Share

  2. SAKOWSKI SA, Koubek EJ, Chen KS, Goutman SA, et al
    Role of the Exposome in Neurodegenerative Disease: Recent Insights and Future Directions.
    Ann Neurol. 2024;95:635-652.
    >> Share

  3. ARVANITAKIS Z, Capuano AW, Tong H, Mehta RI, et al
    Associations of Serum Insulin and Related Measures With Neuropathology and Cognition in Older Persons With and Without Diabetes.
    Ann Neurol. 2024;95:665-676.
    >> Share

    March 2024

  4. Retraction: 5-Lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of alzheimer disease.
    Ann Neurol. 2024 Mar 28. doi: 10.1002/ana.26938.
    >> Share

  5. PALPATZIS E, Akinci M, Aguilar-Dominguez P, Garcia-Prat M, et al
    Lifetime Stressful Events Associated with Alzheimer's Pathologies, Neuroinflammation and Brain Structure in a Risk Enriched Cohort.
    Ann Neurol. 2024 Mar 11. doi: 10.1002/ana.26881.
    >> Share

  6. LACHNER C, Craver EC, Babulal GM, Lucas JA, et al
    Disparate Dementia Risk Factors Are Associated with Cognitive Impairment and Rates of Decline in African Americans.
    Ann Neurol. 2024;95:518-529.
    >> Share

  7. PAPP KV, Jutten RJ, Soberanes D, Weizenbaum E, et al
    Early Detection of Amyloid-Related Changes in Memory among Cognitively Unimpaired Older Adults with Daily Digital Testing.
    Ann Neurol. 2024;95:507-517.
    >> Share

    February 2024
  8. VAN EGROO M, van Someren EJW, Grinberg LT, Bennett DA, et al
    Associations of 24-Hour Rest-Activity Rhythm Fragmentation, Cognitive Decline, and Postmortem Locus Coeruleus Hypopigmentation in Alzheimer's Disease.
    Ann Neurol. 2024 Feb 26. doi: 10.1002/ana.26880.
    >> Share

  9. LI Y, Yen D, Hendrix RD, Gordon BA, et al
    Timing of Biomarker Changes in Sporadic Alzheimer's Disease in Estimated Years from Symptom Onset.
    Ann Neurol. 2024 Feb 24. doi: 10.1002/ana.26891.
    >> Share

  10. PHAN TX, Baratono S, Drew W, Tetreault AM, et al
    Increased Cortical Thickness in Alzheimer's Disease.
    Ann Neurol. 2024 Feb 24. doi: 10.1002/ana.26894.
    >> Share

  11. SALTIEL N, Tripodis Y, Menzin T, Olaniyan A, et al
    Relative Contributions of Mixed Pathologies to Cognitive and Functional Symptoms in Brain Donors Exposed to Repetitive Head Impacts.
    Ann Neurol. 2024;95:314-324.
    >> Share

  12. KUCHENBECKER LA, Tipton PW, Martens Y, Brier MR, et al
    Diagnostic Utility of Cerebrospinal Fluid Biomarkers in Patients with Rapidly Progressive Dementia.
    Ann Neurol. 2024;95:299-313.
    >> Share

  13. CHEN X, Toueg TN, Harrison TM, Baker SL, et al
    Regional Tau Deposition Reflects Different Pathways of Subsequent Neurodegeneration and Memory Decline in Cognitively Normal Older Adults.
    Ann Neurol. 2024;95:249-259.
    >> Share

    January 2024
  14. VANCE JM, Farrer LA, Huang Y, Cruchaga C, et al
    Report of the APOE4 National Institute on Aging/Alzheimer Disease Sequencing Project Consortium Working Group: Reducing APOE4 in Carriers is a Therapeutic Goal for Alzheimer's Disease.
    Ann Neurol. 2024 Jan 5. doi: 10.1002/ana.26864.
    >> Share

    December 2023
  15. BONOMI S, Lu R, Schindler SE, Bui Q, et al
    Relationships of Cognitive Measures with Cerebrospinal Fluid but not Imaging Biomarkers of Alzheimer Disease Vary between Black and White Individuals.
    Ann Neurol. 2023 Dec 1. doi: 10.1002/ana.26838.
    >> Share

    October 2023
  16. ZHENG L, Rubinski A, Dennecke J, Luan Y, et al
    Combined Connectomics, MAPT Gene Expression, and Amyloid Deposition to Explain Regional Tau Deposition in Alzheimer's Disease.
    Ann Neurol. 2023 Oct 14. doi: 10.1002/ana.26818.
    >> Share

  17. GRILL JD, Flournoy C, Dhadda S, Ernstrom K, et al
    Eligibility rates among racially and ethnically diverse US participants in Phase 2 and Phase 3 placebo-controlled, double-blind, randomized trials of lecanemab and elenbecestat in early Alzheimer's disease.
    Ann Neurol. 2023 Oct 13. doi: 10.1002/ana.26819.
    >> Share

  18. DARK HE, Paterson C, Daya GN, Peng Z, et al
    Proteomic indicators of health predict Alzheimer's disease biomarker levels and dementia risk.
    Ann Neurol. 2023 Oct 6. doi: 10.1002/ana.26817.
    >> Share

  19. SHAW LM, Galasko D
    Assessments of the Utilities of CSF NPTX2 for Disease Progression in Cognitively Normal Individuals Who Progress to Clinical MCI and AD.
    Ann Neurol. 2023;94:618-619.
    >> Share

  20. SOLDAN A, Oh S, Ryu T, Pettigrew C, et al
    NPTX2 in Cerebrospinal Fluid Predicts the Progression From Normal Cognition to Mild Cognitive Impairment.
    Ann Neurol. 2023;94:620-631.
    >> Share

    September 2023
  21. HIRATA K, Matsuoka K, Tagai K, Endo H, et al
    Altered brain energy metabolism related to astrocytes in Alzheimer's disease.
    Ann Neurol. 2023 Sep 13. doi: 10.1002/ana.26797.
    >> Share

    August 2023
  22. MINOGUE G, Kawles A, Zouridakis A, Keszycki R, et al
    Distinct Patterns of Hippocampal Pathology in Alzheimer's Disease with TDP-43.
    Ann Neurol. 2023 Aug 18. doi: 10.1002/ana.26762.
    >> Share

  23. KOSIK KS
    Search Strategies for Alzheimer Protector Genes.
    Ann Neurol. 2023 Aug 13. doi: 10.1002/ana.26764.
    >> Share

  24. YU L, Petyuk VA, Lopes KP, Tasaki S, et al
    Associations of VGF with Neuropathologies and Cognitive Health in Older Adults.
    Ann Neurol. 2023;94:232-244.
    >> Share

  25. CHEN XQ, Sawa M, Becker A, Karachentsev D, et al
    Retromer Proteins Reduced in Down Syndrome and the Dp16 Model: Impact of APP Dose and Preclinical Studies of a gamma-Secretase Modulator.
    Ann Neurol. 2023;94:245-258.
    >> Share

    July 2023
  26. KUHLENBAUMER G, Jensen-Kondering U, Margraf NG
    Decreased Cerebrospinal Fluid Amyloid Beta 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy.
    Ann Neurol. 2023;94:205.
    >> Share

  27. LUCEY BP, Liu H, Toedebusch CD, Freund D, et al
    Suvorexant Acutely Decreases Tau Phosphorylation and Abeta in the Human CNS.
    Ann Neurol. 2023;94:27-40.
    >> Share

    June 2023
  28. LUCEY BP, Bateman RJ
    Reply to Suvorexant for preventing Alzheimer's disease.
    Ann Neurol. 2023 Jun 28. doi: 10.1002/ana.26728.
    >> Share

  29. KAWADA T
    Suvorexant for preventing Alzheimer's disease.
    Ann Neurol. 2023 Jun 27. doi: 10.1002/ana.26733.
    >> Share

  30. DE KORT AM, Kuiperij HB, Marques TM, Jakel L, et al
    Decreased Cerebrospinal Fluid Amyloid beta 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy.
    Ann Neurol. 2023;93:1173-1186.
    >> Share

    May 2023
  31. NELSON PT, Schneider JA, Jicha GA, Duong MT, et al
    When Alzheimer's is LATE: Why does it matter?
    Ann Neurol. 2023 May 28. doi: 10.1002/ana.26711.
    >> Share

  32. HOOSHMAND B, Appold F, Fissler P, Perneczky R, et al
    Markers of vitamin B12 status in relation to cerebrospinal fluid biomarkers of Alzheimer's disease and cognitive performance.
    Ann Neurol. 2023 May 12. doi: 10.1002/ana.26673.
    >> Share

  33. ANDRE C, Champetier P, Rehel S, Kuhn E, et al
    Rapid Eye Movement Sleep, Neurodegeneration, and Amyloid Deposition in Aging.
    Ann Neurol. 2023;93:979-990.
    >> Share

    April 2023
  34. NEDELEC T, Couvy-Duchesne B, Darves-Bornoz A, Couronne R, et al
    A comparison between early presentation of dementia with Lewy Bodies, Alzheimer's disease and Parkinson's disease: evidence from routine primary care and UK Biobank data.
    Ann Neurol. 2023 Apr 25. doi: 10.1002/ana.26670.
    >> Share

  35. SHAHID M, Rawls A, Ramirez V, Ryman S, et al
    Illusory Responses across the Lewy Body Disease Spectrum.
    Ann Neurol. 2023;93:702-714.
    >> Share

    March 2023
  36. MUSIEK ES, McDade E, Holtzman DM
    Lecanamab ushers in a new era of anti-amyloid therapy for Alzheimer's Disease.
    Ann Neurol. 2023 Mar 15. doi: 10.1002/ana.26643.
    >> Share

  37. PYUN JM, Park YH, Wang J, Bice PJ, et al
    Aberrant GAP43 gene expression is Alzheimer's disease pathology-specific.
    Ann Neurol. 2023 Mar 10. doi: 10.1002/ana.26637.
    >> Share

  38. LAN G, Guo T
    Reply to: "Aberrant GAP43 gene expression is Alzheimer's disease pathology-specific".
    Ann Neurol. 2023 Mar 10. doi: 10.1002/ana.26639.
    >> Share

  39. TROPEA TF, Albuja I, Cousins KAQ, Irwin DJ, et al
    Concomitant Alzheimer's Disease Pathology in Parkinson's Disease Dementia.
    Ann Neurol. 2023 Mar 9. doi: 10.1002/ana.26635.
    >> Share

  40. YOUNCE JR, Martin WRW, Perlmutter JS
    Reply to "Concomitant Alzheimer's Disease Pathology in Parkinson's Disease Dementia".
    Ann Neurol. 2023 Mar 9. doi: 10.1002/ana.26630.
    >> Share

    February 2023
  41. HORIE K, Li Y, Barthelemy NR, Gordon BA, et al
    Change in cerebrospinal fluid tau microtubule binding region detects symptom onset, cognitive decline, tangles, and atrophy in Dominantly Inherited Alzheimer's Disease.
    Ann Neurol. 2023 Feb 26. doi: 10.1002/ana.26620.
    >> Share

    December 2022
  42. RUBINSKI A, Frerich S, Malik R, Franzmeier N, et al
    Polygenic effect on tau pathology progression in Alzheimer's disease.
    Ann Neurol. 2022 Dec 26. doi: 10.1002/ana.26588.
    >> Share

  43. BEASON-HELD LL, Kerley CI, Chaganti S, Moghekar A, et al
    Health Conditions Associated with Alzheimer's Disease and Vascular Dementia.
    Ann Neurol. 2022 Dec 26. doi: 10.1002/ana.26584.
    >> Share

  44. MENESES AD, Koga S, Li Z, O'Leary J, et al
    APOE2 Exacerbates TDP-43 Related Toxicity in the Absence of Alzheimer Pathology.
    Ann Neurol. 2022 Dec 22. doi: 10.1002/ana.26580.
    >> Share

  45. BRENOWITZ WD, Fornage M, Launer LJ, Habes M, et al
    Alzheimer's disease genetic risk, cognition, and brain aging in midlife.
    Ann Neurol. 2022 Dec 13. doi: 10.1002/ana.26569.
    >> Share

  46. LAHNA D, Schwartz DL, Woltjer R, Black SE, et al
    Venous Collagenosis as Pathogenesis of White Matter Hyperintensity.
    Ann Neurol. 2022;92:992-1000.
    >> Share

    November 2022
  47. MARTIN WRW, Younce JR, Campbell MC, Racette BA, et al
    Neocortical Lewy body pathology parallels Parkinson's dementia, but not always.
    Ann Neurol. 2022 Nov 4. doi: 10.1002/ana.26542.
    >> Share

  48. YAU WW, Shirzadi Z, Yang HS, Ikoba AP, et al
    Tau Mediates Synergistic Influence of Vascular Risk and Abeta on Cognitive Decline.
    Ann Neurol. 2022;92:745-755.
    >> Share

  49. COUSINS KAQ, Shaw LM, Shellikeri S, Dratch L, et al
    Elevated Plasma Phosphorylated Tau 181 in Amyotrophic Lateral Sclerosis.
    Ann Neurol. 2022;92:807-818.
    >> Share

    October 2022
  50. HSU JL, Wei YC, Toh CH, Hsiao IT, et al
    MRI images implicate glymphatic alterations mediate cognitive dysfunction in AD.
    Ann Neurol. 2022 Oct 10. doi: 10.1002/ana.26516.
    >> Share

  51. GOTTESMAN RF, Wu A, Coresh J, Knopman DS, et al
    Associations of Vascular Risk and Amyloid Burden with Subsequent Dementia.
    Ann Neurol. 2022;92:607-619.
    >> Share

    September 2022
  52. JOSEPH-MATHURIN N, Llibre-Guerra JJ, Li Y, McCullough AA, et al
    Amyloid-related imaging abnormalities in the DIAN-TU-001 trial of gantenerumab and solanezumab: lessons from a trial in dominantly inherited Alzheimer disease.
    Ann Neurol. 2022 Sep 24. doi: 10.1002/ana.26511.
    >> Share

  53. CASULA EP, Borghi I, Maiella M, Pellicciari MC, et al
    Regional precuneus cortical hyperexcitability in Alzheimer's disease patients.
    Ann Neurol. 2022 Sep 22. doi: 10.1002/ana.26514.
    >> Share

  54. JOH HK, Kwon H, Son KY, Yun JM, et al
    Allergic diseases and risk of incident dementia and Alzheimer's disease.
    Ann Neurol. 2022 Sep 12. doi: 10.1002/ana.26506.
    >> Share

  55. LAN G, Cai Y, Li A, Liu Z, et al
    Association of presynaptic loss with Alzheimer's disease and cognitive decline.
    Ann Neurol. 2022 Sep 3. doi: 10.1002/ana.26492.
    >> Share

  56. HU H, Bi YL, Shen XN, Ma YH, et al
    Application of the Amyloid/Tau/Neurodegeneration Framework in Cognitively Intact Adults: The CABLE Study.
    Ann Neurol. 2022;92:439-450.
    >> Share

  57. SMIRNOV DS, Salmon DP, Galasko D, Edland SD, et al
    TDP-43 Pathology Exacerbates Cognitive Decline in Primary Age-Related Tauopathy.
    Ann Neurol. 2022;92:425-438.
    >> Share

  58. BACHMANN D, Roman ZJ, Buchmann A, Zuber I, et al
    Lifestyle Affects Amyloid Burden and Cognition Differently in Men and Women.
    Ann Neurol. 2022;92:451-463.
    >> Share

    August 2022
  59. AL-MUBARAK B, Ahmed Nour M, Schumacher-Schuh A, Bandres-Ciga S, et al
    Globalizing research towards diverse representation in Alzheimer's and Parkinson's disease.
    Ann Neurol. 2022 Aug 24. doi: 10.1002/ana.26483.
    >> Share

  60. JOSEPHS KA, Tosakulwong N, Gatto RG, Weigand SD, et al
    Optimum Differentiation of Frontotemporal Lobar Degeneration from Alzheimer Disease Achieved with Cross-Sectional Tau Positron Emission Tomography.
    Ann Neurol. 2022 Aug 15. doi: 10.1002/ana.26479.
    >> Share

  61. RAUCHMANN BS, Brendel M, Franzmeier N, Trappmann L, et al
    Microglial Activation and Connectivity in Alzheimer Disease and Aging.
    Ann Neurol. 2022 Aug 1. doi: 10.1002/ana.26465.
    >> Share

    July 2022
  62. SUN L, Guo D, Jia Y, Shi M, et al
    Association Between Human Blood Metabolome and the Risk of Alzheimer's Disease.
    Ann Neurol. 2022 Jul 28. doi: 10.1002/ana.26464.
    >> Share

  63. HEAD E, Zetterberg H
    Commentary on Oeckl et al., "Serum Beta-Synuclein Is Higher in Down Syndrome and Precedes Rise of pTau181".
    Ann Neurol. 2022;92:3-5.
    >> Share

  64. OECKL P, Wagemann O, Halbgebauer S, Anderl-Straub S, et al
    Serum Beta-Synuclein Is Higher in Down Syndrome and Precedes Rise of pTau181.
    Ann Neurol. 2022;92:6-10.
    >> Share

    June 2022
  65. CASULA EP, Pellicciari MC, Bonni S, Borghi I, et al
    Decreased frontal gamma activity in Alzheimer's disease patients.
    Ann Neurol. 2022 Jun 17. doi: 10.1002/ana.26444.
    >> Share

  66. SCHINDLER SE, Ney DE, Goss AL, Rabinovici G, et al
    ANA Investigates: The Future of Biomarkers in Alzheimer Disease.
    Ann Neurol. 2022 Jun 11. doi: 10.1002/ana.26437.
    >> Share

  67. CORNELIS MC, Bennett DA, Weintraub S, Schneider JA, et al
    Caffeine Consumption and Dementia: Are Lewy Bodies the Link?
    Ann Neurol. 2022;91:834-846.
    >> Share

  68. GRATUZE M, Jiang H, Wang C, Xiong M, et al
    APOE Antibody Inhibits Abeta-Associated Tau Seeding and Spreading in a Mouse Model.
    Ann Neurol. 2022;91:847-852.
    >> Share

    May 2022
  69. BENUSSI A, Cantoni V, Grassi M, Brechet L, et al
    Increasing brain gamma activity improves episodic memory and restores cholinergic dysfunction in Alzheimer's disease.
    Ann Neurol. 2022 May 24. doi: 10.1002/ana.26411.
    >> Share

  70. GANDY S
    A Letter Concerning "Aducanumab: What about the Patient?"
    Ann Neurol. 2022;91:732-733.
    >> Share

    April 2022
  71. BUCKLEY RF, O'Donnell A, McGrath ER, Jacobs HIL, et al
    Menopause status moderates sex differences in tau burden: a Framingham PET Study.
    Ann Neurol. 2022 Apr 26. doi: 10.1002/ana.26382.
    >> Share

    March 2022
  72. LEE YG, Jeon S, Park M, Kang SW, et al
    Effects of Alzheimer's and Lewy Body Disease Pathologies on Brain Metabolism.
    Ann Neurol. 2022 Mar 21. doi: 10.1002/ana.26355.
    >> Share

  73. BENITEZ A, Jensen JH, Thorn K, Dhiman S, et al
    Greater diffusion restriction in white matter in Preclinical Alzheimer's disease.
    Ann Neurol. 2022 Mar 13. doi: 10.1002/ana.26353.
    >> Share

    January 2022
  74. MEYER PF, Ashton NJ, Karikari TK, Strikwerda-Brown C, et al
    Plasma p-tau231, p-tau181, PET biomarkers and cognitive change in older adults.
    Ann Neurol. 2022 Jan 27. doi: 10.1002/ana.26308.
    >> Share

    October 2021
  75. SANDROCK A
    Letter Concerning Medicare Should Not Cover Aducanumab as a Treatment for Alzheimer's Disease by Moghavem, Henderson, and Greicius.
    Ann Neurol. 2021 Oct 23. doi: 10.1002/ana.26254.
    >> Share

  76. DAS SR, Lyu X, Duong MT, Xie L, et al
    Tau-atrophy variability reveals phenotypic heterogeneity in Alzheimer's disease.
    Ann Neurol. 2021 Oct 7. doi: 10.1002/ana.26233.
    >> Share

    September 2021
  77. PETERSEN RC
    Aducanumab: What about the Patient?
    Ann Neurol. 2021;90:334-335.
    >> Share

    July 2021
  78. TAN EK
    Genetic studies of Parkinson's & Alzheimer's disease in Latinos/Hispanics: New Insights & Challenges.
    Ann Neurol. 2021 Jul 26. doi: 10.1002/ana.26179.
    >> Share

  79. MONTAL V, Barroeta I, Bejanin A, Pegueroles J, et al
    Metabolite signature of Alzheimer's disease in adults with Down syndrome.
    Ann Neurol. 2021 Jul 26. doi: 10.1002/ana.26178.
    >> Share

  80. DAUTRICOURT S, de Flores R, Landeau B, Poisnel G, et al
    Longitudinal changes in hippocampal network connectivity in Alzheimer's disease.
    Ann Neurol. 2021 Jul 19. doi: 10.1002/ana.26168.
    >> Share

  81. MOGHAVEM N, Henderson VW, Greicius MD
    Medicare should not cover aducanumab as a treatment for Alzheimer's disease.
    Ann Neurol. 2021 Jul 19. doi: 10.1002/ana.26167.
    >> Share

    May 2021
  82. LIN BSZ, Sur S, Liu P, Li Y, et al
    Blood-brain barrier breakdown in relationship to Alzheimer and vascular disease.
    Ann Neurol. 2021 May 26. doi: 10.1002/ana.26134.
    >> Share

  83. SARIYA S, Felsky D, Reyes-Dumeyer D, Lali R, et al
    Polygenic risk score for Alzheimer's Disease in Caribbean Hispanics.
    Ann Neurol. 2021 May 26. doi: 10.1002/ana.26131.
    >> Share

    April 2021
  84. LUCHICCHI A, Hart B, Frigerio I, van Dam AM, et al
    Axon-Myelin Unit Blistering as Early Event in MS Normal Appearing White Matter.
    Ann Neurol. 2021;89:711-725.
    >> Share

    March 2021
  85. PETERSEN RC, Wiste HJ, Weigand SD, Fields JA, et al
    NIA-AA Alzheimer's Disease Framework: Clinical Characterization of Stages.
    Ann Neurol. 2021 Mar 26. doi: 10.1002/ana.26071.
    >> Share

  86. BUCIUC M, Whitwell JL, Kasanuki K, Graff-Radford J, et al
    Lewy Body Disease is a Contributor to Logopenic Progressive Aphasia Phenotype.
    Ann Neurol. 2021;89:520-533.
    >> Share

    February 2021
  87. KONIJNENBERG E, Tomassen J, den Braber A, Ten Kate M, et al
    The onset of preclinical Alzheimer's disease in monozygotic twins.
    Ann Neurol. 2021 Feb 14. doi: 10.1002/ana.26048.
    >> Share

  88. FILIPPONE A, Pratico D
    Endosome dysregulation in Down syndrome: a potential contributor to Alzheimer's disease pathology.
    Ann Neurol. 2021 Feb 6. doi: 10.1002/ana.26042.
    >> Share

  89. MEEKER KL, Wisch JK, Hudson D, Coble D, et al
    Socioeconomic Status Mediates Racial Differences Seen Using the AT(N) Framework.
    Ann Neurol. 2021;89:254-265.
    >> Share

    December 2020
  90. RAJAN KB, Aggarwal NT, McAninch EA, Weuve J, et al
    Remote Blood Biomarkers of Longitudinal Cognitive Outcomes in a Population Study.
    Ann Neurol. 2020;88:1065-1076.
    >> Share

    November 2020
  91. LESMAN-SEGEV OH, La Joie R, Iaccarino L, Lobach I, et al
    Diagnostic Accuracy of Amyloid versus FDG PET in Autopsy-Confirmed Dementia.
    Ann Neurol. 2020 Nov 20. doi: 10.1002/ana.25968.
    >> Share

  92. BUCKLEY RF, Scott MR, Jacobs HIL, Schultz AP, et al
    Sex Mediates Relationships Between Regional Tau Pathology and Cognitive Decline.
    Ann Neurol. 2020;88:921-932.
    >> Share

    October 2020
  93. TAN S, Baggio D, Shortt J, Ko B, et al
    Cardiovascular Safety of Nilotinib in Alzheimer's Disease.
    Ann Neurol. 2020 Oct 25. doi: 10.1002/ana.25947.
    >> Share

  94. MOUSSA C
    Reply to Cardiovascular Safety of Nilotinib in Alzheimer's Disease.
    Ann Neurol. 2020 Oct 25. doi: 10.1002/ana.25946.
    >> Share

  95. NOYCE AJ, Klein C
    Genetic risk of Alzheimer's disease - Sleepless with the enemy.
    Ann Neurol. 2020 Oct 18. doi: 10.1002/ana.25938.
    >> Share

  96. ESPAY AJ, Marsili L, Mahajan A, Sturchio A, et al
    Rivastigmine in Parkinson's Disease Dementia with Orthostatic Hypotension.
    Ann Neurol. 2020 Oct 5. doi: 10.1002/ana.25923.
    >> Share

    September 2020
  97. ANDREWS SJ, Fulton-Howard B, O'Reilly P, Marcora E, et al
    Causal associations between modifiable risk factors and the Alzheimer's phenome.
    Ann Neurol. 2020 Sep 29. doi: 10.1002/ana.25918.
    >> Share

    August 2020
  98. GHIRELLI A, Tosakulwong N, Weigand SD, Clark HM, et al
    Sensitivity-specificity of tau and Abeta PET in frontotemporal lobar degeneration.
    Ann Neurol. 2020 Aug 31. doi: 10.1002/ana.25893.
    >> Share

    July 2020
  99. NUNEZ C, Callen A, Lombardini F, Compta Y, et al
    Different Cortical Gyrification Patterns in Alzheimer's Disease and Impact on Memory Performance.
    Ann Neurol. 2020;88:67-80.
    >> Share

    June 2020
  100. SCARIONI M, Gami-Patel P, Timar Y, Seelaar H, et al
    Frontotemporal Dementia: Correlations Between Psychiatric Symptoms and Pathology.
    Ann Neurol. 2020;87:950-961.
    >> Share

  101. BUCKLEY R, Pascual-Leone A
    Age-Related Cognitive Decline Is Indicative of Neuropathology.
    Ann Neurol. 2020;87:813-815.
    >> Share

    May 2020
  102. MATIAS-GUIU JA, Cabrera-Martin MN, Pytel V, Montero P, et al
    Amyloid PET in Multiple Sclerosis: between amyloid deposition and myelin damage.
    Ann Neurol. 2020 May 1. doi: 10.1002/ana.25759.
    >> Share

    April 2020
  103. ZEYDAN B, Kantarci K, Kantarci OH
    Reply to "Amyloid PET in Multiple Sclerosis: between amyloid deposition and myelin damage".
    Ann Neurol. 2020 Apr 30. doi: 10.1002/ana.25758.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016